The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The US Food and Drug Administration has approved the first ever prescribed medicine for Obstructive Sleep Apnea. Read on to ...

Logistic regression analysis showed that only AHI was a predictor of daytime hypercapnia ... daytime hypercapnia may be directly linked to sleep apnea in a subgroup of patients with OSAS.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

4.1.2. Evidence That Portable Monitors Can Be Used to Increase the Probability That a Patient Has An Abnormal AHI If a portable monitor is going to be used to rule in a diagnosis of sleep apnea ...

"This is a major step forward for patients with obstructive sleep apnea ... had a mean change at week 52 in the apnea-hypopnea index (AHI) of 25.3 fewer events per hour with tirzepatide in ...

The trials’ main goal was improvement on a metric known as the apnea-hypopnea index, or AHI, the number of breathing ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

For individuals with mmOSA, CRP levels were associated with hypertension risk and insulin resistance among those aged less than 60 years.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...